Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)

Date

07 Oct 2016

Session

Genitourinary tumours, prostate

Presenters

Johann de Bono

Citation

Annals of Oncology (2016) 27 (6): 243-265. 10.1093/annonc/mdw372

Authors

J.S. de Bono1, U. De Giorgi2, C. Massard3, S. Bracarda4, D. Nava Rodrigues1, I. Kocak5, A. Font Pous6, J. Arranz Arija7, K. Shih8, G.D. Radavoi9, W. Yu10, W. Chan10, S. Gendreau10, L. Zhang10, R. Riisnaes1, M.J. Wongchenko10, D. Maslyar10, V. Jinga9

Author affiliations

  • 1 The Royal Marsden, Institute of Cancer Research, SW3 6JJ - London/GB
  • 2 Medical Oncology, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT
  • 3 Medicine, Institut Gustave Roussy, Villejuif/FR
  • 4 Department Of Oncology, Ospedale San Donato and U.O.C. of Medical Oncology, 52100 - Arezzo/IT
  • 5 Oncology, Masaryk Memorial Cancer Institute, Brno/CW
  • 6 Institut Català D'oncologia, Hospital Universitari Germans Trias i Pujol, 08916 - Badalona/ES
  • 7 Servicio De Oncologia Medica, Hospital General Universitario Gregorio Marañon, 28007 - Madrid/ES
  • 8 Oncology, Tennessee Oncology, Nashville/US
  • 9 Oncology, ”Carol Davila” University of Medicine and Pharmacy, Bucharest/RO
  • 10 Oncology, Genentech, Inc., 94080 - South San Francisco/US
More

Resources

Reserved to ESMO members
View the presentation

Background

PTEN loss, which leads to elevated PI3K/Akt pathway activation, is one of the most common changes in mCRPC and is associated with a worse prognosis. Ipatasertib (Ipat) is a potent, novel oral ATP-competitive inhibitor of Akt. When combined with abiraterone acetate (Abi), Ipat improved radiographic progression-free survival (rPFS) and overall survival in unselected patients (pts) with mCRPC (de Bono et al, ASCO 2016). In this analysis, rPFS in pts with PTEN loss was assessed, and the relationship between PTEN expression by immunohistochemistry (IHC) and genomic loss of PTEN was further explored.

Methods

Pts with mCRPC, previously treated with docetaxel, were randomized 1:1:1 (double blinded) to 3 arms: Ipat-400 mg, Ipat-200 mg or placebo (Pbo) in combination with Abi 1000 mg and prednisone 10 mg daily. PTEN expression was assessed by IHC in archival or fresh tumor samples, with prospectively defined criteria for PTEN loss. PTEN genomic loss was detected by fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS).

Results

253 pts were randomized and 173 rPFS events (68%) were observed at the primary analysis. PTEN status was IHC evaluable in 165 cases, with PTEN loss reported in 71 cases (43%). PTEN loss was associated with a worse rPFS outcome in the Pbo arm, while Ipat improved rPFS compared with Pbo at both doses, with a greater treatment effect at 400 mg and in PTEN-loss cancers (Table). There was high concordance for PTEN loss between FISH, NGS and IHC.

PTEN Loss Non-PTEN Loss
Ipat-400 + Abi (n = 25) Ipat-200 + Abi (n =25) Pbo + Abi (n =21) Ipat-400 + Abi (n = 32) Ipat-200 + Abi (n = 27) Pbo + Abi (n = 35)
rPFS events, n % 15 (60) 16 (64) 18 (86) 20 (63) 20 (74) 26 (74)
Median, months 11.5 11.1 4.6 7.5 4.6 5.6
Unstratified HR 0.39 0.46 0.84 1.13
90% CI 0.22-0.70 0.25-0.83 0.51-1.37 0.69-1.85
P value 0.0064 0.0285 0.5647 0.6762

Conclusions

This study indicates that combining Akt inhibition with improved AR pathway blockade in mCRPC may provide pt benefit and is the first clinical demonstration supporting PTEN loss as a predictive response biomarker for mCRPC. These findings warrant the co-development of Ipat with a companion diagnostic assay to select mCRPC pts with PTEN loss and improve outcomes. NCT01485861.

Clinical trial identification

NCT01485861

Legal entity responsible for the study

F. Hoffmann La-Roche

Funding

F. Hoffmann La-Roche

Disclosure

J.S. de Bono: Genentech Advisory Board meetings as a paid consultant. C. Massard: Genentech, Astellas, Medimmune, Ipsen, Jansen, Novartis, Pfizer, Roche, Sanofi, Orion, New Oncology.

S. Bracarda: Advisory Board Member for: Bayer, Pfizer, Astellas, BMS, Novartis, Exelixis, Roche. Honoraria: Pfizer, Novartis, Astellas, Bayer, BMS. W. Yu, W. Chan, S. Gendreau, L. Zhang, M.J. Wongchenko, D. Maslyar: Employee and shareholder of Genentech/Roche.

All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings